The PD‐L1‐targeting humanized IgG1 monoclonal antibody atezolizumab received accelerated FDA approval in May 2020 as first‐line therapy for advanced NSCLC with high PD‐L1 expression, based on groundbreaking outcomes from the Phase III IMpower110 trial (NCT02409342) [25]. Here, CD274 is linked to non-small cell lung carcinoma.